AMCP CEO Blog: One of AMCP’s key strategic pillars is to advocate for legislation that will help advance the profession of managed care pharmacy. This function is on full display this week during our Annual Legislative Days event.
On March 5, 2018, AMCP provided comments in response to the Advance Summary of Methodological Changes for Calendar Year (CY) 2018 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2018 Call Letter. AMCP comments focus on the sections of the notice related to CMS's proposal on several new strategies for identifying potential opioid abuse.
The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in response to the notice titled “Advance Summary of Methodological Changes for Calendar Year (CY) 2018 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2018 Call Letter” released on February 1, 2018.
Leg-Reg Briefing March 2018: Congress Set to Recess This Week Final Call Letter, Part D Rule Expected April 2nd State Legislative and Advocacy Activity
The Academy of Managed Care Pharmacy (AMCP) writes to support and express concerns with specific provisions of Senate Bill 350. This legislation would regulate biological products and substitution of interchangeable biological products when dispensed by pharmacists.
The Academy of Managed Care Pharmacy (AMCP) writes to support and express concerns with specific provisions of Senate Bill 92. This legislation would regulate biological products and substitution of interchangeable biological products when dispensed by pharmacists.
The Academy of Managed Care Pharmacy (AMCP) is writing to express concerns with specific provisions of House Bill 4524. This legislation would regulate biological products and substitution of interchangeable biological products when dispensed by pharmacists.